Matinas BioPharma Holdings (MTNB) Other Non-Current Liabilities (2015 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Other Non-Current Liabilities of $1.3 million for Q1 2025, up 1414.77% quarter-over-quarter from $88000.0 in Q4 2022.
Matinas BioPharma Holdings (MTNB) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other Non-Current Liabilities for 5 consecutive years, with $1.3 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Other Non-Current Liabilities changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2025 stood at $1.3 million (changed N/A YoY), while the FY2022 annual figure was $88000.0, down 90.21% from the prior year.
- Other Non-Current Liabilities improved to $1.3 million in Q1 2025 per MTNB's latest filing, from $88000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.3 million in Q1 2025 and bottomed at $88000.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $642888.9 across 3 years, with a median of $669000.0 in 2022.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 337.25% in 2022 and fell as far as 90.21% in 2022.
- Matinas BioPharma Holdings' Other Non-Current Liabilities stood at $899000.0 in 2021, then sank by 90.21% to $88000.0 in 2022, then surged by 1414.77% to $1.3 million in 2025.
- Business Quant data shows MTNB's Other Non-Current Liabilities at $1.3 million in Q1 2025, $88000.0 in Q4 2022, and $194000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 444,000.00 |
| Mar 31, 2022 | 669,000.00 |
| Dec 31, 2021 | 899,000.00 |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 807,000.00 |
| Mar 31, 2021 | 153,000.00 |
| Dec 31, 2020 | 899,000.00 |
| Sep 30, 2015 | 781,729.00 |